It is unsurprising that, for the primary outcome (hospitalizations) among the asthma-only population, results did not reach statistical significance.
← all excerpts
Comment on Albogami et al. Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344-1352.
1
—
—